Similar articles

Abstract: To assess the influence of cyclosporin A (CsA) and tacrolimus (FK506) on mycophenolic acid (MPA) and correlation analysis of the pharmacokinetic parameters and patient characteristics, clinical outcome in Chinese kidney transplant recipients, the pharmacokinetics of 1000 mg mycophenolate mofetil (MMF) twice daily was measured by high-performance liquid chromatography (HPLC). PKS (Pharmaceutical Kinetics Software) 1.0.2 software package was used for the calculation of pharmacokinetic parameters. The mean C_max, t_max, and AUC₍₀₋₁₂₎were (21.88±10.52) µg/ml, (1.20±0.95) h, and (52.546±13.215) µg·h/ml, respectively. The level of AUC₍₀₋₁₂₎ in the FK506 group was significantly higher than that in the CsA group. MPA appeared not to be affected by renal function. MPA AUC₍₀₋₁₂₎ showed statistically significant difference according to the patient’s gender.

[1] Bullingham, R.E., Nicholls, A., Hale, M., 1996a. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant. Proc., 28(2):925-929.

[2] Bullingham, R.E., Monroe, S., Nicholls, A., Hale, M., 1996b. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol., 36(4):315-324.

[3] Bullingham, R.E., Nicholls, A.J., Kamm, B.R., 1998. Pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet., 34(6):429-455.

[4] Cho, E.K., Han, D.J., Kim, S.C., Burckart, G.J., Venkataramanan, R., Oh, J.M., 2004. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J. Clin. Pharmacol., 44(7):743-750.

[5] European Mycophenolate Mofetil Cooperative Study Group, 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet., 345(8961):1321-1325.

[6] Filler, G., Zimmering, M., Mai, I., 2000. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr. Nephrol., 14(2):100-104.

[7] Gregoor, P.J., de Sevaux, R.G., Hene, R.J., Hesse, C.J., Hilbrands, L.B., Vos, P., van Gelder, T., Hoitsma, A.J., Weimar, W., 1999. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation, 68(10):1603-1606.

[8] Johnson, A.G., Rigby, R.J., Taylor, P.J., Jones, C.E., Allen, J., Franzen, K., Falk, M.C., Nicol, D., 1999. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther., 66(5):492-500.

[9] Kuriata-kordek, M., Boratynska, M., Falkiewicz, K., Porazko, T., Urbaniak, J., Wozniak, M., Patrzalek, D., Szyber, P., Klinger, M., 2003. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant. Proc., 35(6):2369-2371.

[10] Lee, H.J., Pawlak, K., Nguyen, B.T., Robinsm, R.K., Sadee, W., 1985. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studies in mouse lymphoma cell culture. Cancer Res., 45:5512-5520.

[11] Matsuzawa, Y., Nakase, T., 1984. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. J. Pharmacobiodyn., 7(10):776-783.

[12] Pescovitz, M.D., Guasch, A., Gaston, R., Rajagopalan, P., Tomlanovich, S., Weinstein, S., Bumgardner, G.L., Melton, L., Ducray, P.S., Banken, L., et al., 2003. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant., 3(12):1581-1586.

[13] Rasom, J.T., 1995. Mechanism of action of mycophenolate mofetil. Ther. Drug. Monit., 17(6):681-684.

[14] Shaw, L.M., Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, I, Keown, P., Holt, D.W., Lieberman, R., 1995. Mycophenolate mofetil: A report of the consensus panel. Ther. Drug. Monit., 17(6):690-699.

[15] Shaw, L.M., Nicholl, A., Hale, M., Armstrong, V.W., Oellerich, M., Yatscoff, R., Morris, R.E., Holt, D.W., Venkataramanan, R., Haley, J., et al., 1998. Therapeutic monitoring of mycophenolic acid: A consensus panel report. Clin. Biochem., 31(5):317-322.

[16] Shaw, L.M., Kaplan, B., DeNofrio, D., Korecka, M., Brayman, K.L., 2000. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther. Drug. Monit., 22(1):14-19.

[17] Shaw, L.M., Pawinski, T., Korecka, M., Nawrocki, A., 2002. Monitoring of mycophenolic acid in clinical transplantation. Ther. Drug. Monit., 24(1):68-73.

[18] Takahashi, K., Ochiai, T., Uchida, K., Yasumara, T., Ishibashi, M., Suzuki, S., Otsubo, O., Isono, K., Takagi, H., Oka, T., 1995. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee−Japan. Transplant. Proc., 27(1):1421-1424.

[19] Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, 1996. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61(7):1029-1037.

[20] Young, C.J., Sollinger, H.W., 1994. RS-61443: A new immunosuppressive agent. Transplant. Proc., 26(6):3144-3146.

[21] Zucker, K., Rosen, A., Tsaroucha, A., de Faria, L., Roth, D., Ciancio, G., Esquenazi, V., Burke, G., Tzakis, A., Miller, J., 1997. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mucophenolate mofetil in combination therapy, an analogous in vitro findings. Transpl. Immunol., 5(3):225-232.

[22] Zucker, K., Tsaroucha, A., Olsen, L., Esquenazi, V., Tzakis, A., Miller, J., 1999. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug. Monit., 21(1):35-43.